{"name":"Paul Saenger","slug":"paul-saenger","ticker":"","exchange":"","domain":"","description":"Paul Saenger is a pharmaceutical company with a focus on early-stage clinical development, currently advancing one drug in Phase 1 trials. The company's pipeline is centered around innovative therapies, though limited public information is available.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiW0FVX3lxTFBCS2YyWXdydlQ3VkpKSGctY3RQSXNvTXYwT3JQU2p6WWlVdXpaQngyNk02MFdCTTUyMFFSVWd3OHcweTdTZVVqLWZXYXctSkxkbWJLQl80TWtmd0E?oc=5","date":"2023-03-13","type":"pipeline","source":"EurekAlert!","summary":"Pediatric Investigation review takes stock of history and current status of long-acting growth hormone therapy - EurekAlert!","headline":"Pediatric Investigation review takes stock of history and current status of long-acting growth hormone therapy - EurekAl","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}